Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
-
- STATUS
- Recruiting
-
- End date
- Dec 24, 2023
-
- participants needed
- 2200
-
- sponsor
- Makerere University
Summary
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis. Though the available literature is mostly from observational study designs, and is fraught with controversy, BCG vaccination at birth, in a high risk population of HIV exposed children, may protect infants against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy, when the immune system is more mature, may offer even greater protection. The appropriate timing of BCG vaccination could therefore be up for revision. This study will therefore compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV exposed (HE) babies.
Methods: This is an individually randomized clinical trial in 4,500 HIV exposed infants. The intervention is an intra-dermal administration of 0.05 ml of BCG vaccine within 24 hours of birth while the comparator will be an intra-dermal administration of 0.05ml of BCG vaccine at 14 weeks of age.
The main study outcomes include:
- Severe illness in the first 14 weeks of life,
- TNF, IL-1b, IL-6 and IFN- in response to mycobacterial and non-mycobacterial antigens and
- Severe illness in the first 14-52 weeks and 0-52 weeks of life.
The study will be carried in two health Center IIIs and a health center IV in Uganda.
Implications: A well-timed BCG vaccination could have important additional benefits in HE infants. This trial could inform the development of programmatically appropriate timing of BCG vaccination for HE infants.
Details
| Condition | Severe Illness, Septicaemia, Diarrhoea, Malaria, Lower Respiratory Infection |
|---|---|
| Treatment | BCG at birth, Control arm: Delayed BCG |
| Clinical Study Identifier | NCT02606526 |
| Sponsor | Makerere University |
| Last Modified on | 23 February 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer